Seladelpar

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 83 publications

Peroxisome Proliferator-Activated Receptor α/δ/γ Activation Profile by Endogenous Long-Chain Fatty Acids.

Peroxisome Proliferator-Activated Receptor α/δ/γ Activation Profile by Endogenous Long-Chain Fatty Acids.

Journal: International journal of molecular sciences

Published: November 12, 2025

Recent Advances in Primary Biliary Cholangitis Treatment.

Recent Advances in Primary Biliary Cholangitis Treatment.

Journal: Clinics in liver disease

Published: October 18, 2025

An update on novel investigational agents for the treatment of primary biliary cholangitis.

An update on novel investigational agents for the treatment of primary biliary cholangitis.

Journal: Expert opinion on investigational drugs

Published: October 13, 2025

Beyond Ursodeoxycholic Acid: A Comprehensive Review of Second-Line Agents in Primary Biliary Cholangitis.

Beyond Ursodeoxycholic Acid: A Comprehensive Review of Second-Line Agents in Primary Biliary Cholangitis.

Journal: Cureus

Published: October 08, 2025

Primary biliary cholangitis. Treatment options in 2025. A narrative review.

Primary biliary cholangitis. Treatment options in 2025. A narrative review.

Journal: Frontiers in immunology

Published: September 04, 2025

Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor.

Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor.

Journal: Biomedicines

Published: August 27, 2025

Correction: The role of Seladelpar in primary biliary cholangitis: a systematic review and meta-analysis.

Correction: The role of Seladelpar in primary biliary cholangitis: a systematic review and meta-analysis.

Journal: BMC gastroenterology

Published: August 20, 2025

Primary biliary cholangitis-Update on diagnostics, risk stratification and new treatment options

Primary biliary cholangitis-Update on diagnostics, risk stratification and new treatment options

Journal: Innere Medizin (Heidelberg, Germany)

Published: August 20, 2025

Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications.

Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications.

Journal: Current therapeutic research, clinical and experimental

Published: August 07, 2025

Reviewing novel findings and advances in diagnoses and treatment of primary biliary cholangitis.

Reviewing novel findings and advances in diagnoses and treatment of primary biliary cholangitis.

Journal: Expert review of gastroenterology & hepatology

Published: July 30, 2025

Optimizing Care in Primary Biliary Cholangitis: Current Treatments and the Second-Line Decision.

Optimizing Care in Primary Biliary Cholangitis: Current Treatments and the Second-Line Decision.

Journal: Digestive diseases and sciences

Published: July 10, 2025

Fracture events in patients with primary biliary cholangitis during treatment with seladelpar in the phase III RESPONSE trial.

Fracture events in patients with primary biliary cholangitis during treatment with seladelpar in the phase III RESPONSE trial.

Journal: Hepatology communications

Published: July 01, 2025

Showing 1-12 of 83

Last Updated: 02/24/2026